Ipsen S.A. ADR (IPSEY) 14.8000 $IPSEY
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 7.63 (+0.03)
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 7.63 (+0.03)
Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma
BusinessWire - Mon May 23, 1:31PM CDT
Regulatory News:
EXEL: 7.63 (+0.03)
Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen's Paris-Saclay Campus
BusinessWire - Tue May 03, 12:39PM CDT
--Oncodesign teams are moving to Ipsen's private open innovation campus in Paris-Saclay
IPN: 28.70 (+1.12)
Ipsen's First Quarter 2016 Sales
BusinessWire - Thu Apr 28, 12:00AM CDT
--Specialty care sales up 9.7%(1), driven by the accelerated growth of Somatuline(R) in neuroendocrine tumors
Probi and Ipsen Sign Extensive Primary Care Distribution Agreement for Probiotic LP299V(R), Lactobacillus plantarum 299v
BusinessWire - Tue Apr 26, 1:45AM CDT
Regulatory News:
Ipsen is Pleased to Announce That Its Partner Exelixis Obtained FDA Approval of CABOMETYX(TM) (cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
BusinessWire - Mon Apr 25, 5:27PM CDT
--In February 2016, Exelixis and Ipsen entered into an exclusive licensing agreement to develop and commercialize cabozantinib in regions outside the United States, Canada and Japan
EXEL: 7.63 (+0.03)
Dassault Systemes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen's drug discovery
BusinessWire - Tue Apr 05, 12:00AM CDT
Regulatory News:
Exelixis Inc. Stock Was Throttled in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 06, 10:03AM CST
What: Shares of Exelixis , a biopharmaceutical company focused on the development of therapies to treat cancer, plunged 20% in February, based on data from S&P Global Market Intelligence . The two likely culprits appear to be market sentiment...
BMY: 71.33 (+0.66), EXEL: 7.63 (+0.03)
Ipsen report on voting rights and number of shares
M2 - Tue Feb 09, 6:57AM CST
Ipsen SA (Paris:IPN.PA) on Monday reported that as on 28 January 2016, the total number of shares in the company was 83,245,602.
Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport(R) (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy
BusinessWire - Tue Jan 26, 1:14PM CST
Regulatory News:
Ipsen and Galderma Expand Current Distribution Agreement for Dysport(R) in Aesthetic Indications to Some Key Asia-Pacific Territories(1)
BusinessWire - Wed Jan 06, 12:00AM CST
Regulatory News:
Ipsen purchases 20,000 of own shares
M2 - Wed Dec 23, 5:21AM CST
Ipsen SA (Paris :IPN) on Tuesday reported that from 14 December 2015 to 18 December 2015, it has purchased a total of 20,000 of its own shares.
IPN: 28.70 (+1.12)
Ipsen Announces Its Corporate Agenda for 2016
BusinessWire - Thu Dec 17, 12:10PM CST
Regulatory News:
Ipsen reports on share purchase from 30 November to 4 December 2015
M2 - Tue Dec 08, 6:26AM CST
Ipsen SA (Paris:IPN) on Monday reported that during the period from 30 November 2015 to 4 December 2015, it purchased a total of 20,000 of its shares.
IPN: 28.70 (+1.12)
Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
GlobeNewswire - Mon Nov 16, 6:30AM CST
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the enrollment of the first subjects in a Phase 1 clinical safety trial of OTO-311, a product candidate for the treatment of tinnitus. OTO-311 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. This Phase 1 dose escalation clinical safety study is being conducted in normal healthy volunteers. OTO-311 will be given as a single unilateral intratympanic injection and subjects will be observed for four weeks following dosing.
OTIC: 15.48 (+0.50), IPN: 28.70 (+1.12)
Ipsen: sales in the 3rd quarter and first nine months of 2015
BusinessWire - Thu Oct 29, 1:00AM CDT
--Primary care sales down 5.0%(1), in a challenging environment in France and emerging markets
Exelixis and Its Partner Ipsen Announce Positive Overall Survival Results from Subgroup Analyses of Phase 3 Trial of CABOMETYX(TM) (cabozantinib) Tablets in Advanced Renal Cell Carcinoma at 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 6:36AM CDT
--ABSTRACT #4557, #4558
EXEL: 7.63 (+0.03)
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX(TM) (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
BusinessWire - Sun Jun 05, 6:36AM CDT
--Overall survival and progression-free survival benefits consistent across all subgroups evaluated
EXEL: 7.63 (+0.03)
Ipsen's partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma
BusinessWire - Mon May 23, 1:31PM CDT
Regulatory News:
EXEL: 7.63 (+0.03)
Oncodesign and Ipsen Enter into a Strategic Partnership in Oncology and Oncodesign Joins Ipsen's Paris-Saclay Campus
BusinessWire - Tue May 03, 12:39PM CDT
--Oncodesign teams are moving to Ipsen's private open innovation campus in Paris-Saclay
IPN: 28.70 (+1.12)
Ipsen's First Quarter 2016 Sales
BusinessWire - Thu Apr 28, 12:00AM CDT
--Specialty care sales up 9.7%(1), driven by the accelerated growth of Somatuline(R) in neuroendocrine tumors
Probi and Ipsen Sign Extensive Primary Care Distribution Agreement for Probiotic LP299V(R), Lactobacillus plantarum 299v
BusinessWire - Tue Apr 26, 1:45AM CDT
Regulatory News:
Ipsen is Pleased to Announce That Its Partner Exelixis Obtained FDA Approval of CABOMETYX(TM) (cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
BusinessWire - Mon Apr 25, 5:27PM CDT
--In February 2016, Exelixis and Ipsen entered into an exclusive licensing agreement to develop and commercialize cabozantinib in regions outside the United States, Canada and Japan
EXEL: 7.63 (+0.03)
Dassault Systemes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen's drug discovery
BusinessWire - Tue Apr 05, 12:00AM CDT
Regulatory News:
Exelixis Inc. Stock Was Throttled in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Sun Mar 06, 10:03AM CST
What: Shares of Exelixis , a biopharmaceutical company focused on the development of therapies to treat cancer, plunged 20% in February, based on data from S&P Global Market Intelligence . The two likely culprits appear to be market sentiment...
BMY: 71.33 (+0.66), EXEL: 7.63 (+0.03)
Ipsen report on voting rights and number of shares
M2 - Tue Feb 09, 6:57AM CST
Ipsen SA (Paris:IPN.PA) on Monday reported that as on 28 January 2016, the total number of shares in the company was 83,245,602.
Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safety of Dysport(R) (abobotulinumtoxinA) in children with dynamic equinus foot deformity due to cerebral palsy
BusinessWire - Tue Jan 26, 1:14PM CST
Regulatory News:
Ipsen and Galderma Expand Current Distribution Agreement for Dysport(R) in Aesthetic Indications to Some Key Asia-Pacific Territories(1)
BusinessWire - Wed Jan 06, 12:00AM CST
Regulatory News:
Ipsen purchases 20,000 of own shares
M2 - Wed Dec 23, 5:21AM CST
Ipsen SA (Paris :IPN) on Tuesday reported that from 14 December 2015 to 18 December 2015, it has purchased a total of 20,000 of its own shares.
IPN: 28.70 (+1.12)
Ipsen Announces Its Corporate Agenda for 2016
BusinessWire - Thu Dec 17, 12:10PM CST
Regulatory News:
Ipsen reports on share purchase from 30 November to 4 December 2015
M2 - Tue Dec 08, 6:26AM CST
Ipsen SA (Paris:IPN) on Monday reported that during the period from 30 November 2015 to 4 December 2015, it purchased a total of 20,000 of its shares.
IPN: 28.70 (+1.12)
Otonomy Initiates Phase 1 Clinical Trial for Tinnitus Product Candidate, OTO-311
GlobeNewswire - Mon Nov 16, 6:30AM CST
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the enrollment of the first subjects in a Phase 1 clinical safety trial of OTO-311, a product candidate for the treatment of tinnitus. OTO-311 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine. This Phase 1 dose escalation clinical safety study is being conducted in normal healthy volunteers. OTO-311 will be given as a single unilateral intratympanic injection and subjects will be observed for four weeks following dosing.
OTIC: 15.48 (+0.50), IPN: 28.70 (+1.12)
Ipsen: sales in the 3rd quarter and first nine months of 2015
BusinessWire - Thu Oct 29, 1:00AM CDT
--Primary care sales down 5.0%(1), in a challenging environment in France and emerging markets
